New research is shedding light on surprising ways to reduce chronic inflammation—including suggestions as simple as flossing ...

Pregnant individuals with inflammatory bowel disease (IBD) have higher levels of pro-inflammatory immune molecules, known as cytokines, in their ...

Published in Volume 1 of the journal Immunity & Inflammation on December 18, 2025, the article "Reinventing brain immunity in neurodegeneration ...

The TOGETHER-PsA study shows that combining ixekizumab with tirzepatide leads to significantly better psoriatic arthritis ...

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected ...

Detailed price information for Tvardi Therapeutics Inc (TVRD-Q) from The Globe and Mail including charting and trades.

Two patients present with rash eruptions on different parts of the body. Can you correctly identify each case?

Breakthrough Therapy Designation granted for investigational therapy IPN60340 in combination with venetoclax and azacitidine ...

On November 2, 2025, the research group led by Dr. Zeng Ling from Army Medical University systematically elucidated the molecular mechanisms, ...

The hemophagocytic lymphohistiocytosis market is expected to increase due to the launch of emerging therapies, such as plonmarlimab (TJ Biopharma), ELA026 (Electra Therapeutics), MAS825 (Novartis) ...

New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung function LA JOLLA, CA, Jan. 08, 2026 (GLOBE NEWSWIRE) ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory ...